We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BIO, Novartis Urge Supreme Court to Overturn Patent Eligibility Test
BIO, Novartis Urge Supreme Court to Overturn Patent Eligibility Test
August 21, 2009
The Biotechnology Industry Organization (BIO) and Novartis are urging the U.S. Supreme Court to overturn a lower court’s ruling in a patent eligibility case — a decision that will determine the threshold a patent application must meet to be examined for novelty, inventiveness or usefulness.